Resumo
Definição
História e exame físico
Principais fatores diagnósticos
- presença de fatores de risco
- despigmentação acral e periorificial
- despigmentação perianal e genital
- trauma cutâneo recente
- dor localizada por queimadura solar
- intensificação e fluorescência com exposição a ultravioleta A (UV-A)
- nevo halo
- despigmentação universal
Fatores de risco
- idade <30 anos
- história familiar de vitiligo
- doença autoimune
- contato com produtos químicos
Investigações diagnósticas
Primeiras investigações a serem solicitadas
- diagnóstico clínico
Investigações a serem consideradas
- Exame com a lâmpada de Wood
- biópsia de pele
Algoritmo de tratamento
vitiligo segmentar ou vitiligo limitado
vitiligo disseminado (mais de 3% da área de superfície corporal)
Colaboradores
Autores
John E. Harris, MD, PhD
Professor
Department of Dermatology
University of Massachusetts Medical School
Worcester
MA
Declarações
JEH has acted as a consultant and/or investigator for: Pfizer, Genzyme/Sanofi, Aclaris Therapeutics Inc., Incyte, Rheos Medicines, Sun Pharmaceuticals, LEO Pharma, Villaris Therapeutics Inc., Dermavant, Temprian, AbbVie Inc., Janssen, TeVido, BioDevices, EMD Serono, Almirall, Boston Pharma, Sonoma Biotherapeutics Inc., Methuselah Health, Twi Biotech, Pandion, Cogen Therapeutics Inc., Admirx, BridgeBio, AnaptysBio, Avita, Frazier Management. He has equity in TeVido Biodevices, Rheos, and Villaris Therapeutics Inc., and is the Scientific Founder of Villaris Therapeutics Inc. JEH is an author of a number of references cited in this topic.
Mehdi Rashighi, MD
Assistant Professor
Department of Dermatology
University of Massachusetts Medical School
Worcester
MA
Declarações
MR has received consulting fees and/or research grants from the following: Pfizer, AbbVie, Dermavant, LEO Pharma, and Almirall. MR is an author of a reference cited in this topic.
Agradecimentos
Professor John E. Harris and Dr Mehdi Rashighi would like to gratefully acknowledge Dr Bernhard Ortel, a previous contributor to this topic. BO declares that he has no competing interests.
Revisores
Iltefat Hamzavi, MD
Senior Staff Physician
Multicultural Dermatology Center
Henry Ford Hospital
Detroit
MI
Declarações
IH is an author of a number of references cited in this topic.
Piergiacomo Calzavara-Pinton, MD
Chair
Dermatology Department
University of Brescia
Brescia
Italy
Declarações
PC-P is an author of a number of references cited in this topic.
Diagnósticos diferenciais
- Piebaldismo
- Síndrome de Waardenburg
- Esclerose tuberosa
Mais Diagnósticos diferenciaisDiretrizes
- British Association of Dermatologists guidelines for the management of people with vitiligo 2021
- Guidelines for the management of vitiligo
Mais Diretrizes
Conectar-se ou assinar para acessar todo o BMJ Best Practice
O uso deste conteúdo está sujeito ao nosso aviso legal